Aeterna Zentaris to Announce Fourth Quarter and Year End 2018 Financial and Operating Results on March 26, 2019
March 19 2019 - 8:00AM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)
will announce its fourth quarter and year ended December 31, 2018
financial and operating results after market close on Tuesday,
March 26, 2019.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company
focused on commercializing novel pharmaceutical therapies,
principally through out-licensing arrangements. Aeterna Zentaris is
a party to a license and assignment agreement with a subsidiary of
Novo Nordisk A/S to carry out development, manufacturing,
registration and commercialization of Macrilen™ (macimorelin) in
the United States and Canada. For more information, visit
www.zentaris.com.
Forward-Looking Statements
This press release contains forward-looking statements (as
defined by applicable securities legislation) made pursuant to the
safe-harbor provision of the U.S. Securities Litigation Reform Act
of 1995, which reflect our current expectations regarding future
events. Forward-looking statements may include, but are not
limited to statements preceded by, followed by, or that include the
words "will," "expects," "believes," "intends," "would," "could,"
"may," "anticipates," and similar terms that relate to future
events, performance, or our results. Forward-looking statements
involve known and unknown risks and uncertainties, including those
discussed in this press release and in our Annual Report on Form
20-F, under the caption "Key Information - Risk Factors" filed with
the relevant Canadian securities regulatory authorities in lieu of
an annual information form and with the U.S. Securities and
Exchange Commission. Known and unknown risks and uncertainties
could cause our actual results to differ materially from those in
forward-looking statements. Such risks and uncertainties include,
among others, our now heavy dependence on the success of Macrilen™
(macimorelin) and related out-licensing arrangements and the
continued availability of funds and resources to successfully
launch the product, our strategic review process, the ability of
the Special Committee to carry out its mandate, the ability of
Aeterna Zentaris to enter into out-licensing, development,
manufacturing and marketing and distribution agreements with other
pharmaceutical companies and keep such agreements in effect,
reliance on third parties for the manufacturing and
commercialization of our product candidates, potential disputes
with third parties, leading to delays in or termination of the
manufacturing, development, out-licensing or commercialization of
our product candidates, or resulting in significant litigation or
arbitration, and, more generally, uncertainties related to the
regulatory process, our ability to efficiently commercialize or
out-license Macrilen™ (macimorelin), the degree of market
acceptance of Macrilen™ (macimorelin), our ability to obtain
necessary approvals from the relevant regulatory authorities to
enable us to use the desired brand names for our products, the
impact of securities class action litigation or other litigation on
our cash flow, results of operations and financial position, our
ability to take advantage of business opportunities in the
pharmaceutical industry, our ability to protect our intellectual
property, the potential of liability arising from shareholder
lawsuits and general changes in economic conditions. Investors
should consult our quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks
and uncertainties. Given these uncertainties and risk factors,
readers are cautioned not to place undue reliance on these
forward-looking statements. We disclaim any obligation to update
any such factors or to publicly announce any revisions to any of
the forward-looking statements contained herein to reflect future
results, events or developments, unless required to do so by a
governmental authority or applicable law.
Contacts:Aeterna Zentaris Inc.Leslie AuldChief
Financial OfficerIR@aezsinc.com843-900-3211
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024